Hostname: page-component-74656f9884-j7cmm Total loading time: 0 Render date: 2026-11-10T10:40:54.610Z Has data issue: false hasContentIssue false
  • English
  • Français

Introduction

Published online by Cambridge University Press:  16 April 2020

JJ Lopez-Ibor
JJ Lopez-Ibor*
Affiliation:
Psychiatric Unit, San Carlos Hospital, Complutense University, Martin Lago S/N, 28040, Madrid, Spain
Get access

Summary

In the past serendipity and good clinical observation were essential for the discovery of new drug treatments for mental disorders. Today, neurochemical and pharmacological research allows development of compounds starting from hypothesis on the origin of the disorders and the actions of available drugs. The new compounds are cleaner from the pharmacological point of view, more specific and therefore with less undesired effects. Venlafaxine is one of these drugs and provides antidepressant efficacy in a broad range of depressed patients, including the most severe ones, with a good safety and tolerability profile.

Keywords

antidepressantsserotonin reuptake inhibitorsserotonin-noradrenaline reuptake inhibitorsdepressive disorders (pharmacotherapy)

Information

Type
Introduction
Information
European Psychiatry , Volume 12 , Issue S4 , 1997 , pp. 283s - 284s
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Baron, BM, Ogden, A-M, Siegel, BWet al.Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988; 154: 125–134CrossRefGoogle ScholarPubMed
Bolden-Watson, C, Richelson, EBlockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023–1029CrossRefGoogle ScholarPubMed
Cusack, B, Nelson, A, Richelson, EBinding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114: 559–565CrossRefGoogle ScholarPubMed
Muth, EA, Moyer, JA, Haskins, JT, Andree, TH, Husbands, GEMBiochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23: 191–199CrossRefGoogle Scholar
Nelson, JC, Mazure, CM, Bowers, MB, Jatlow, PIA preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303–307CrossRefGoogle ScholarPubMed
Preskorn, SHAntidepressant drug selection: Criteria and options. J Clin Psychiatry 1994 55 (suppl) 6–24Google ScholarPubMed
Seth, R, Jennings, AL, Bindman, Jet al.Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992; 161: 562–565CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.